

References QBRI Insights: An Overview of the COVID-19 Pandemic

1. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet*. 2020;395(10224):565-74.
2. Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. *Chinese medical journal*. 2020.
3. Du Toit A. Outbreak of a novel coronavirus. *Nature reviews Microbiology*. 2020;18(3):123.
4. World Health Organization. Available at: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>.
5. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020.
6. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med*. 2020;382(13):1199-207.
7. Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. *Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi*. 2020.
8. (WHO) WHO. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Available at: <https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf>. 2020.
9. Novel Coronavirus Pneumonia Emergency Response Epidemiology T. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. *Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi*. 2020;41(2):145-51.
10. World Health Organization. Coronavirus disease 2019 (COVID-19). Situation Report – 77. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200406-sitrep-77-covid-19.pdf?sfvrsn=21d1e632_2.
11. CDC guidelines and information for Laboratories. Available at <https://www.cdc.gov/coronavirus/2019-ncov/lab/index.html>.
12. Park M, Cook AR, Lim JT, Sun Y, Dickens BL. A Systematic Review of COVID-19 Epidemiology Based on Current Evidence. *Journal of Clinical Medicine*. 2020;9(4):967.
13. Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. *Jama*. 2020.
14. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet (London, England)*. 2020;395(10223):497-506.
15. Huang G, Gong T, Wang G, Wang J, Guo X, Cai E, et al. Timely Diagnosis and Treatment Shortens the Time to Resolution of Coronavirus Disease (COVID-19) Pneumonia and Lowers

the Highest and Last CT Scores From Sequential Chest CT. *AJR American journal of roentgenology*. 2020:1-7.

16. Sharfstein JM, Becker SJ, Mello MM. Diagnostic Testing for the Novel Coronavirus. *JAMA*. 2020.

17. Wang Y, Kang H, Liu X, Tong Z. Combination of RT-qPCR Testing and Clinical Features For Diagnosis of COVID-19 facilitates management of SARS-CoV-2 Outbreak. *Journal of medical virology*. 2020.

18. Hadaya J, Schumm M, Livingston EH. Testing Individuals for Coronavirus Disease 2019 (COVID-19). *JAMA*. 2020.

19. Sheridan C. Fast, portable tests come online to curb coronavirus pandemic. *Nature biotechnology*. 2020.

20. European Centre for Disease Prevention and Control. An overview of the rapid test situation for COVID-19 diagnosis in the EU/EEA. 1 April 2020. Stockholm: ECDC; 2020. Available at <https://www.ecdc.europa.eu/en/publications-data/overview-rapid-test-situation-covid-19-diagnosis-eueea>.

21. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents*. 2020:105949.

22. Molina JM, Delaugerre C, Goff JL, Mela-Lima B, Ponscarne D, Goldwirt L, et al. *Med Mal Infect*. 2020.

23. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727-33.

24. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*. 2020.

25. Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. *Cell Mol Immunol*. China2020.

26. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. *Lancet*. 2020;395(10223):e30-e1.

27. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Biosci Trends*. 2020;14(1):72-3.

28. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *Clin Infect Dis*. 2020.

29. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res*. 30. England2020. p. 269-71.

30. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First Case of 2019 Novel Coronavirus in the United States. *N Engl J Med*. 2020;382(10):929-36.
31. Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). *Nat Rev Drug Discov*. 19. England2020. p. 149-50.
32. Morse JS, Lalonde T, Xu S, Liu WR. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. *Chembiochem*. 2020;21(5):730-8.
33. Yan L, Jinyong Z, Ning W, Haibo L, Yun S, Gang G, et al. Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput Screening2020.
34. Zhou W, Liu Y, Tian D, Wang C, Wang S, Cheng J, et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. *Signal Transduct Target Ther*. 2020;5:18.
35. Drugmakers Rush to Develop Vaccines Against China Virus. Available at: <https://www.wsj.com/articles/drugmakers-rush-to-develop-vaccines-against-china-virus-11579813026> 2020.
36. China fast-tracks novel coronavirus vaccine development. Available at: http://www.xinhuanet.com/english/2020-01/28/c_138739378.htm 2020.
37. mRNA Vaccines Can Induce Immune Responses for 2019-nCoV. Available at: <https://www.precisionvaccinations.com/curevac-mrna-platform-specifically-suitable-rapidly-provide-answer-viral-outbreak-situation-novel>. 2020.
38. Inovio Selected by CEPI to Develop Vaccine Against New Coronavirus. Available at: <http://ir.inovio.com/news-and-media/news/press-release-details/2020/Inovio-Selected-by-CEPI-to-Develop-Vaccine-Against-New-Coronavirus/default.aspx>. 2020.
39. An obscure biotech stock skyrockets 38% after saying it's testing a coronavirus antibody (VIR). Available at: <https://markets.businessinsider.com/news/stocks/vir-biotechnology-stock-price-surges-coronavirus-antibody-tests-crispr-2020-1-1028847912>. 2020.
40. Vir Biotechnology applying multiple platforms to address public health risk from Wuhan coronavirus. Available at: <https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-applying-multiple-platforms-address-public>. 2020.
41. China coronavirus: Hong Kong researchers have already developed vaccine but need time to test it, expert reveals. Available at: <https://www.scmp.com/news/hong-kong/health-environment/article/3047956/china-coronavirus-hong-kong-researchers-have>. 2020.